Magnetar Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Magnetar Financial’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,760	Closed	-$352K	–	776
2022 Q3	$352K	Sell	1,760 -14,627	-89%	-$2.79M	﹤0.01%	868
2022 Q2	$2.39M	Buy	+16,387	New	+$2.32M	0.02%	607
2021 Q2	–	Sell	-1,980	Closed	-$280K	–	1189
2021 Q1	$280K	Sell	1,980 -1,628	-45%	-$245K	﹤0.01%	934
2020 Q4	$469K	Buy	+3,608	New	+$482K	0.01%	572
2018 Q2	–	Sell	-4,603	Closed	-$548K	–	491
2018 Q1	$548K	Buy	+4,603	New	+$593K	0.01%	316
2015 Q4	–	Sell	-5,612	Closed	-$451K	–	353
2015 Q3	$451K	Buy	5,612 +3,369	+150%	+$374K	0.01%	233
2015 Q2	$269K	Buy	+2,243	New	+$268K	﹤0.01%	378

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Magnetar Financial's ALNY Position: Q4 2022 in Review

Magnetar Financial sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2022, closing a stake of 1,760 shares — an estimated $352K sold.

Magnetar Financial first reported a position in ALNY in Q2 2015 and held it in 7 quarters. The position peaked at $2.39M in Q2 2022. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

Magnetar Financial reported no remaining Alnylam Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Magnetar Financial sold 1,760 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $352K.
Magnetar Financial first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 7 quarters.
Magnetar Financial's Alnylam Pharmaceuticals position peaked at $2.39M in Q2 2022.
487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Magnetar Financial's 13F filing for Q4 2022, filed 14 Feb 2023.